Primary results of LORELEI
Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal patients with ER+/HER2-negative early breast cancer (EBC)[LBA10_PR]
Potential Biomarkers of Immunotherapy in NSCLC
Comprehensive Genomic Profiling (CGP) Uncovered Potential Biomarkers of Immunotherapy in NSCLC – Good Predictive Markers: TMB-H, BRAF and MET; Poor Predictive Marker: STK11 [1138PD]
Atezolizumab in Combination with Bevacizumab
Atezolizumab in Combination with Bevacizumab in Untreated mRCC: Updated Analysis of IMmotion150 Study [LBA39] Powles T, et al.
Selective Inhibition Mechanism of RVX-208
Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.